Legal Battle To Limit Patent Filings Continues, But Pharma Industry Wins One Victory
This article was originally published in The Pink Sheet Daily
Executive Summary
The Federal Circuit finds one new patent rule invalid, but decisions on other rules to limit patent examinations are remanded to lower court. GSK is “heartened” by ruling, but acknowledges “the war continues.”